000650 仁和药业
已收盘 09-21 15:00:00
资讯
新帖
简况
仁和药业(000650)9月18日股东户数8.8万户，较上期减少1.01%
证券之星 · 17:38
仁和药业(000650)9月18日股东户数8.8万户，较上期减少1.01%
仁和药业：截至2026年9月18日，大约8.80万户左右
证券之星 · 15:07
仁和药业：截至2026年9月18日，大约8.80万户左右
股市必读：仁和药业(000650)股东户数8.89万户，较上期减少0.56%
证券之星 · 09-14
股市必读：仁和药业(000650)股东户数8.89万户，较上期减少0.56%
仁和药业：截至2026年9月10日，大约8.89万户左右
证券之星 · 09-11
仁和药业：截至2026年9月10日，大约8.89万户左右
仁和药业：公司2022年半年报全文和摘要已披露终止明月仁和矿泉水项目
证券之星 · 09-09
仁和药业：公司2022年半年报全文和摘要已披露终止明月仁和矿泉水项目
仁和药业：如果达到中期分红条件，公司会在2026年下半年进行中期分红
证券之星 · 09-09
仁和药业：如果达到中期分红条件，公司会在2026年下半年进行中期分红
仁和药业：截至2026年8月31日，大约8.94万户左右
证券之星 · 09-09
仁和药业：截至2026年8月31日，大约8.94万户左右
仁和药业：截至2026年8月31日，大约8.94万户左右
证券之星 · 09-07
仁和药业：截至2026年8月31日，大约8.94万户左右
仁和药业(000650)8月31日股东户数8.94万户，较上期减少1%
证券之星 · 09-03
仁和药业(000650)8月31日股东户数8.94万户，较上期减少1%
仁和药业（000650）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-27
仁和药业（000650）2026年中报简析：营收净利润同比双双增长
仁和药业：公司销售的产品都是公司的产品
证券之星 · 08-26
仁和药业：公司销售的产品都是公司的产品
图解仁和药业中报：第二季度单季净利润同比增长20.18%
证券之星 · 08-26
图解仁和药业中报：第二季度单季净利润同比增长20.18%
公司问答丨仁和药业：公司自有产品有很多 如仁和可立克、仁和优卡丹、闪亮滴眼露、妇炎洁系列等
格隆汇 · 08-24
公司问答丨仁和药业：公司自有产品有很多 如仁和可立克、仁和优卡丹、闪亮滴眼露、妇炎洁系列等
公司问答丨仁和药业：仁和氧氟沙星胶囊等是公司生产和销售的抗生素类产品
格隆汇 · 08-24
公司问答丨仁和药业：仁和氧氟沙星胶囊等是公司生产和销售的抗生素类产品
股市必读：仁和药业(000650)股东户数9.03万户，较上期增加1.92%
证券之星 · 08-24
股市必读：仁和药业(000650)股东户数9.03万户，较上期增加1.92%
仁和药业：截至2026年8月20日，大约9.03万户左右
证券之星 · 08-21
仁和药业：截至2026年8月20日，大约9.03万户左右
仁和药业：与西部证券达成全面战略合作协议
证券之星 · 08-20
仁和药业：与西部证券达成全面战略合作协议
仁和药业：强化巩固“中药+化药+大健康”业务布局
证券之星 · 08-19
仁和药业：强化巩固“中药+化药+大健康”业务布局
股市必读：仁和药业（000650）8月18日董秘有最新回复
证券之星 · 08-19
股市必读：仁和药业（000650）8月18日董秘有最新回复
公司问答丨仁和药业：ULOOK眼镜处于销售测试和改进阶段 技术成熟稳定后即可量产
格隆汇 · 08-18
公司问答丨仁和药业：ULOOK眼镜处于销售测试和改进阶段 技术成熟稳定后即可量产
加载更多
公司概况
公司名称：
仁和药业股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-10
主营业务：
仁和药业股份有限公司的主营业务是药品及大健康产品的生产和销售。公司的主要产品是药品、健康相关产品。
发行价格：
6.26
{"stockData":{"symbol":"000650","market":"SZ","secType":"STK","nameCN":"仁和药业","latestPrice":5.33,"timestamp":1789974210000,"preClose":5.18,"halted":0,"volume":26071078,"delay":0,"changeRate":0.029,"floatShares":1331000000,"shares":1400000000,"eps":0.282,"marketStatus":"已收盘","change":0.15,"latestTime":"09-21 15:00:00","open":5.19,"high":5.35,"low":5.18,"amount":138000000,"amplitude":0.0328,"askPrice":5.33,"askSize":164,"bidPrice":5.32,"bidSize":2306,"shortable":0,"etf":0,"ttmEps":0.282,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790040600000},"marketStatusCode":5,"adr":0,"adjPreClose":5.18,"symbolType":"stock","openAndCloseTimeList":[[1789954200000,1789961400000],[1789966800000,1789974000000]],"highLimit":5.7,"lowLimit":4.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1399938234,"isCdr":false,"pbRate":1.11,"roa":"--","peRate":18.900709,"roe":"4.52%","epsLYR":0.28,"committee":-0.599805,"marketValue":7462000000,"turnoverRate":0.0196,"status":0,"floatMarketCap":7096000000},"requestUrl":"/m/hq/s/000650","defaultTab":"news","newsList":[{"id":"2669619154","title":"仁和药业(000650)9月18日股东户数8.8万户，较上期减少1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669619154?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:38","pubTimestamp":1789983519,"startTime":"0","endTime":"0","summary":"证券之星消息，近日仁和药业披露，截至2026年9月18日公司股东户数为8.8万户，较9月10日减少900.0户，减幅为1.01%。在中药行业个股中，仁和药业股东户数高于行业平均水平，截至9月18日，中药行业平均股东户数为5.23万户。从股价来看，2026年9月10日至2026年9月18日，仁和药业区间跌幅为3.0%，在此期间股东户数减少900.0户，减幅为1.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100022562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0188","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669153379","title":"仁和药业：截至2026年9月18日，大约8.80万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2669153379","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669153379?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:07","pubTimestamp":1789974442,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2026年9月20日A股股东人数是多少？谢谢仁和药业回复：尊敬的投资者，谢谢您的关注，截至2026年9月18日，大约8.80万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100013473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0239","BK0097","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667638131","title":"股市必读：仁和药业(000650)股东户数8.89万户，较上期减少0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667638131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667638131?lang=zh_cn&edition=full","pubTime":"2026-09-14 03:34","pubTimestamp":1789328051,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，仁和药业报收于5.21元，下跌2.43%，换手率1.45%，成交量19.31万手，成交额1.01亿元。当日关注点交易信息汇总：9月11日主力资金净流入222.28万元，占总成交额2.21%。股本股东变化：截至2026年9月10日，仁和药业股东户数为8.89万户，较8月31日减少500户，减幅0.56%。请问贵公司2026年9月10日A股股东人数是多少？谢谢董秘： 尊敬的投资者，谢谢您的关注，截至2026年9月10日，大约8.89万户左右。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400001563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0097","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512411","title":"仁和药业：截至2026年9月10日，大约8.89万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666512411?lang=zh_cn&edition=full","pubTime":"2026-09-11 09:15","pubTimestamp":1789089308,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2026年9月10日A股股东人数是多少？谢谢仁和药业回复：尊敬的投资者，谢谢您的关注，截至2026年9月10日，大约8.89万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100016166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0097","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666306569","title":"仁和药业：公司2022年半年报全文和摘要已披露终止明月仁和矿泉水项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2666306569","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666306569?lang=zh_cn&edition=full","pubTime":"2026-09-09 09:15","pubTimestamp":1788916528,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！贵公司总投资5亿元建设的明月仁和矿泉水项目一期已完成投资建成了吗？谢谢！仁和药业回复：尊敬的投资者，谢谢您的关注！公司2022年半年报全文和摘要已披露终止明月仁和矿泉水项目。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900008775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666306835","title":"仁和药业：如果达到中期分红条件，公司会在2026年下半年进行中期分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2666306835","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666306835?lang=zh_cn&edition=full","pubTime":"2026-09-09 09:12","pubTimestamp":1788916331,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！本月底后就要出三季报了。请问贵公司的中期分红符合分红条件吗？什么时候能分红呢？请及时回复！谢谢。仁和药业回复：尊敬的投资者，谢谢您的提醒，根据公司披露的2026年第8号公告-关于授权董事会制定2026年中期分红方案的公告，如果达到中期分红条件，公司会在2026年下半年进行中期分红。请您留意关注公司后续公告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900008679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","000650","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666030576","title":"仁和药业：截至2026年8月31日，大约8.94万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2666030576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666030576?lang=zh_cn&edition=full","pubTime":"2026-09-09 09:06","pubTimestamp":1788915974,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问：敬爱的董秘大人，公司9月2号股东人数多少仁和药业回复：谢谢您的关注，公司证券部没有9月2日股东人数数据。截至2026年8月31日，大约8.94万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900008517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0188","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665113396","title":"仁和药业：截至2026年8月31日，大约8.94万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2665113396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665113396?lang=zh_cn&edition=full","pubTime":"2026-09-07 11:36","pubTimestamp":1788752183,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，公司最新一期（8月31号）的股东人数多少，仁和药业回复：谢谢您的关注，截至2026年8月31日，大约8.94万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700010397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878094","title":"仁和药业(000650)8月31日股东户数8.94万户，较上期减少1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878094","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664878094?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:30","pubTimestamp":1788427831,"startTime":"0","endTime":"0","summary":"证券之星消息，近日仁和药业披露，截至2026年8月31日公司股东户数为8.94万户，较8月20日减少900.0户，减幅为1.0%。在中药行业个股中，仁和药业股东户数高于行业平均水平，截至8月31日，中药行业平均股东户数为5.15万户。从股价来看，2026年8月20日至2026年8月31日，仁和药业区间跌幅为2.85%，在此期间股东户数减少900.0户，减幅为1.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300031530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","000650","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759740","title":"仁和药业（000650）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759740","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662759740?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:22","pubTimestamp":1787782949,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期仁和药业发布2026年中报。根据财报显示，仁和药业营收净利润同比双双增长。截至本报告期末，公司营业总收入20.91亿元，同比上升5.87%，归母净利润2.92亿元，同比上升0.52%。按单季度数据看，第二季度营业总收入9.62亿元，同比下降2.8%，第二季度归母净利润1.52亿元，同比上升20.18%。本文数据来源于仁和药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700011532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662763157","title":"仁和药业：公司销售的产品都是公司的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2662763157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662763157?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:18","pubTimestamp":1787703502,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司所出售的所有非处方药产品，全部是贴牌产品还是有很少部分是公司自己研发生产的自有产品？谢谢！仁和药业回复：尊敬的投资者，谢谢您的关注！公司销售的产品都是公司的产品，无论是自有生产还是OEM代工生产，公司始终把产品质量放在首位。自有产品是根本，OEM是有益补充。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600014102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","000650","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662751776","title":"图解仁和药业中报：第二季度单季净利润同比增长20.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662751776","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662751776?lang=zh_cn&edition=full","pubTime":"2026-08-26 03:14","pubTimestamp":1787685281,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业2026年中报显示，上半年度公司主营收入20.91亿元，同比上升5.87%；归母净利润2.92亿元，同比上升0.52%；扣非净利润2.53亿元，同比上升22.43%；其中2026年第二季度，公司单季度主营收入9.62亿元，同比下降2.8%；单季度归母净利润1.52亿元，同比上升20.18%；单季度扣非净利润1.17亿元，同比上升11.95%；负债率11.85%，投资收益1533.07万元，财务费用52.42万元，毛利率35.96%。财报数据概要请见下图:本文数据来源于仁和药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600005496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661240882","title":"公司问答丨仁和药业：公司自有产品有很多 如仁和可立克、仁和优卡丹、闪亮滴眼露、妇炎洁系列等","url":"https://stock-news.laohu8.com/highlight/detail?id=2661240882","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661240882?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:15","pubTimestamp":1787562956,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["002782","BK0097","BK0214","000650","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661229216","title":"公司问答丨仁和药业：仁和氧氟沙星胶囊等是公司生产和销售的抗生素类产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2661229216","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661229216?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:01","pubTimestamp":1787558494,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0188","000650","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661024558","title":"股市必读：仁和药业(000650)股东户数9.03万户，较上期增加1.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661024558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661024558?lang=zh_cn&edition=full","pubTime":"2026-08-24 02:18","pubTimestamp":1787509093,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，仁和药业报收于5.37元，下跌4.45%，换手率3.08%，成交量40.98万手，成交额2.22亿元。股本股东变化：截至2026年8月20日，仁和药业股东户数为9.03万户，较8月10日增长1.92%，户均持股数量降至1.55万股。敬请发布截至昨天8月20日公司的股东户数信息，谢谢！董秘： 谢谢您的关注，截至2026年8月20日，大约9.03万户左右。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400001135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","000650","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250196","title":"仁和药业：截至2026年8月20日，大约9.03万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250196","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661250196?lang=zh_cn&edition=full","pubTime":"2026-08-21 15:06","pubTimestamp":1787295987,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2026年8月20日A股股东人数是多少？谢谢仁和药业回复：谢谢您的关注，截至2026年8月20日，大约9.03万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100021985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0188","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660699282","title":"仁和药业：与西部证券达成全面战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2660699282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660699282?lang=zh_cn&edition=full","pubTime":"2026-08-20 20:51","pubTimestamp":1787230267,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月19日在投资者关系平台上答复投资者关心的问题。投资者提问：三个月前，仁和药业和西部证券达成战略合作。公司是医药企业，西部证券是金融企业，两家公司合作的范围有哪些？对公司带来哪些益处？仁和药业回复：尊敬的投资者，去年公司与西部证券达成全面战略合作协议，根据协议，仁和药业与西部证券将充分发挥各自在产业资源、资本运作、金融服务及市场拓展等方面的核心优势，建立长期、稳定、互惠的战略合作关系。详细情况请您查阅公司官网相关内容。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000041878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0183","BK0097","BK0239","BK0276","BK0028","002673","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660458354","title":"仁和药业：强化巩固“中药+化药+大健康”业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2660458354","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660458354?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:27","pubTimestamp":1787128026,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月19日在投资者关系平台上答复投资者关心的问题。投资者提问：根据公司新闻，公司荣获“2026中国中成药企业综合竞争力50强”。请问：公司获得该榜单的核心竞争力有哪些？谢谢仁和药业回复：尊敬的投资者，您好！既是荣誉也是证明。仁和药业地处中国药都樟树市，公司强化巩固“中药+化药+大健康”业务布局，加大中药研发、生产、品牌投入，持续推进古代经典名方、中药智能制造的战略定位，这也符合国家中医药振兴政策方向。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900027991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000650","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499729","title":"股市必读：仁和药业（000650）8月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660499729?lang=zh_cn&edition=full","pubTime":"2026-08-19 02:02","pubTimestamp":1787076140,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，仁和药业报收于5.46元，下跌0.18%，换手率1.42%，成交量18.97万手，成交额1.04亿元。董秘最新回复投资者： 近期，创新药股票如哈药股份、百花医药等股票走势均翻倍。公司于2025年8月21日在香港新设成立仁和国际投资控股（香港）有限公司，2025年报全文里有披露。公司2026年第一季度报告显示，公司一季度归母净利1.4亿元，扣非净利1.36亿元，扣非同比增长33.20%，说明公司主营业绩有较好的增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0097","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660468660","title":"公司问答丨仁和药业：ULOOK眼镜处于销售测试和改进阶段 技术成熟稳定后即可量产","url":"https://stock-news.laohu8.com/highlight/detail?id=2660468660","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660468660?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:25","pubTimestamp":1787041547,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","000650","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789990675108,"stockEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":-0.046},{"period":"3month","weight":0.0372},{"period":"6month","weight":-0.0599},{"period":"1year","weight":-0.1814},{"period":"ytd","weight":-0.0582}],"compareEarnings":[{"period":"1week","weight":0.0061},{"period":"1month","weight":0.0045},{"period":"3month","weight":-0.0437},{"period":"6month","weight":-0.0114},{"period":"1year","weight":0.0209},{"period":"ytd","weight":-0.0144}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"仁和药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"88000人(较上一季度减少1.01%)","perCapita":"15129股","listingDate":"1996-12-10","address":"江西省宜春市樟树市葛玄路6号","registeredCapital":"139993万元","survey":" 仁和药业股份有限公司的主营业务是药品及大健康产品的生产和销售。公司的主要产品是药品、健康相关产品。","listedPrice":6.26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仁和药业,000650,仁和药业股票,仁和药业股票老虎,仁和药业股票老虎国际,仁和药业行情,仁和药业股票行情,仁和药业股价,仁和药业股市,仁和药业股票价格,仁和药业股票交易,仁和药业股票购买,仁和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}